Patents Examined by Christina Bradley
  • Peptide-linked ester prodrugs activated by prostate-specific antigen
    Patent number: 11129901
    Abstract: The present disclosure is directed to a series of target-selective chemotherapeutic ester prodrugs comprising PSA-cleavable peptides that promote the delivery of free doxorubicin and other chemotherapeutic agents into the prostate and/or prostate tumors with greater efficiency.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: September 28, 2021
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Longqin Hu, Herve Aloysius
  • De novo design of potent and selective interleukin mimetics
    Patent number: 11117944
    Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??c heterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: September 14, 2021
    Assignees: University Of Washington, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Daniel Adriano Silva Manzano, Shawn Yu, Umut Ulge, David Baker, Kenan Christopher Garcia, Jamie Spangler, Carl Walkey, Alfredo Quijano Rubio, Brian Weitzner
  • Angiotensin II alone or in combination for the treatment of hypotension
    Patent number: 11096983
    Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 6.5 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: August 24, 2021
    Assignee: The George Washington University a Congressionally Chartered Not-for-Profit Corporation
    Inventor: Lakhmir S. Chawla
  • Coiled-coil connector
    Patent number: 11090381
    Abstract: A connector of a helical coiled coil-type structure connecting a first and a second molecule, wherein the first molecule comprises a peptidic first alpha-helix and the second molecule comprises a peptidic second alpha-helix, which second alpha-helix is coiled to the first alpha-helix. The first alpha-helix comprises a C-terminal region consisting of a repeat of an amino acid motif a-x1 and the C-terminal motif a-x1-x2, or an N-terminal region consisting of a repeat of an amino acid motif x1-a and the N-terminal motif x2-x1-a, where a is a motif sequence of 4-8 amino acids, x1 is Lysine, and x2 is an extension of the motif. The extension consists of 1-10 amino acids and does not comprise more than 4 consecutive amino acids incorporated in said motif a-x1 or x1-a. In a multimeric protein, two polypeptide chains can be connected to each other by such connector.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: August 17, 2021
    Assignee: ONCOQR ML GMBH
    Inventors: Geert Mudde, Jorge Sepulveda, Christopher Taus, Liesbeth Mudde-Boer
  • Peptide macrocycles and use thereof in the treatment of bacterial infections
    Patent number: 11091514
    Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R8?, R9, R9?, X1, X2, X3, X4, X5, X6, X7, X8, X9 and X10 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baurnannii.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: August 17, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Konrad Bleicher, Jérôme Hert, Carsten Kroll, Fabian Dey
  • Ubiquitin interacting motif peptides as therapeutics
    Patent number: 11084852
    Abstract: The present disclosure describes the use peptides of comprising ubiquitin interacting motifs (UIMs) alone or in combination with other agents to treat conditions such as cancer, atherosclerosis and obesity.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: August 10, 2021
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Yunzhou Dong, Hong Chen
  • Cyclic peptide conjugates and methods of use
    Patent number: 11078235
    Abstract: The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: August 3, 2021
    Assignees: H. Lee Moffitt Cancer Center And Research Institute, Inc., The Scripps Research Institute, University of South Florida
    Inventors: Lori Hazlehurst, Christoph Rader, Xiuling Li, Mark McLaughlin
  • Immunostimulating peptides
    Patent number: 11072638
    Abstract: The invention provides for novel immunostimulating peptides, peptide constructs and compositions. Further, the invention provides for methods of treatment utilising the peptides, peptide constructs and compositions.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: July 27, 2021
    Assignee: Aimvion A/S
    Inventor: Shervin Bahrami
  • Conjugates for targeting and clearing aggregates
    Patent number: 11065336
    Abstract: In some embodiments, the disclosure provides for a conjugate comprising: a) a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor; and b) a targeting moiety that targets molecular aggregates. In some embodiments, the disclosure provides for methods of using the conjugates for treating a disease or disorder associated with aggregate formation.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: July 20, 2021
    Assignee: MEDIMMUNE LIMITED
    Inventors: Damian C. Crowther, Maria Herva, Roland Bürli, Lutz Jermutus
  • Method of ameliorating side effects of sickle cell disease treatments
    Patent number: 11065277
    Abstract: A method of reducing a cerebral tissue pathology associated with a sickle cell disease therapy in a subject is provided using (i) a synthetic high-oxygen affinity hemoglobin-containing molecule or (ii) synthetically treated high-oxygen affinity blood.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: July 20, 2021
    Assignee: Albert Einstein College of Medicine
    Inventors: Craig Branch, Seetharama Acharya
  • Reconstituted high density lipoprotein formulation and production method thereof
    Patent number: 11058747
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: July 13, 2021
    Assignee: CSL LIMITED
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • Fibroin-derived protein composition
    Patent number: 11045524
    Abstract: A protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: June 29, 2021
    Assignee: Silk Technologies, Ltd.
    Inventors: Brian D. Lawrence, David W. Infanger
  • Method for purifying and quantifying thrombin and its degradation polypeptides
    Patent number: 11008560
    Abstract: Provided is a method for purifying ?-thrombin and for quantifying ?-thrombin and its degradation polypeptides in a liquid proteinatious solution. The method employs a one-step anion exchange chromatography method. The method allows purification and/or quantification of a homogenous post-translationally modified ?-thrombin. The method can also be used for purification and/or quantification of ?-thrombin.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: May 18, 2021
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Tamar Auerbach-Nevo, Nadav Orr, Israel Nur
  • Compositions and methods for treating neonatal biliary atresia
    Patent number: 11000577
    Abstract: Disclosed are methods and compositions for treatment of a subject having a biliary disorder. The methods include administering a therapeutically effective amount of a serine protease inhibitor to a subject in need thereof. The biliary disorder may include biliary atresia, a biliopathy, Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), and combinations thereof. In certain aspects, the serine protease inhibitor may be a protease inhibitor rC1 Inhibitor.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: May 11, 2021
    Assignee: Children's Hospital Medical Center
    Inventor: Pranav-Kumar Shivakumar
  • Peptidic self-assembly for nucleic acid delivery
    Patent number: 11000599
    Abstract: A polypeptide conjugate for use in a method for binding and/or internalization of the polypeptide conjugate to a mammalian cell having a transferrin receptor (TFRC) and/or receptor for advanced glycation end products (RAGE). The polypeptide conjugate may be used in a method for targeting of a drug delivery system or diagnostic delivery system.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: May 11, 2021
    Assignee: S. M. Discovery Group Inc.
    Inventors: Seyed Moien Moghimi, Linping Wu, Davoud Ahmadvand, Ladan Parhamifar
  • Composition and methods for treating ischemic wounds and inflammatory conditions
    Patent number: 10980863
    Abstract: Methods, compositions, and treatment protocols for treating ischemic wounds and inflammatory conditions in a patient. The treatment protocols comprise or consist of using a modified collagen gel (MCG) to promote healing of ischemic wounds and reduce inflammation at the wound site and in other inflammatory conditions. The modified collagen gel comprises generally a dispersion of collagens in an aqueous matrix comprising water and glycerine, where the amount of Type I collagen is greater than the amount of Type II and Type III collagens in the gel.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: April 20, 2021
    Assignee: Southwest Technologies, Inc.
    Inventors: Edward I. Stout, Chandan K. Sen
  • Method of manufacturing a pharmaceutical composition
    Patent number: 10981955
    Abstract: The present invention relates to crystalline forms of carbetocin, a method of their manufacture, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: April 20, 2021
    Assignee: FERRING B.V.
    Inventors: Elizabeth Serrano Chavez, Helen Sjoergren, Jette Boll, Hayley Reece, Jonathan James Loughrey
  • Glucokinase activator compositions for the treatment of diabetes
    Patent number: 10980861
    Abstract: The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: April 20, 2021
    Assignee: vTv Therapeutics LLC
    Inventors: Maria Carmen Valcarce Lopez, Tung Fong
  • Methods of treating cardiomyopathy associated with genetic disorders
    Patent number: 10973869
    Abstract: The present invention provides, among other things, methods of treating a cardiac disease or condition in a patient having muscular dystrophy that can include administering to a subject suffering from, susceptible, or diagnosed with muscular dystrophy an angiotensin (1-7) peptide.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: April 13, 2021
    Assignee: Constant Therapeutics LLC
    Inventor: Richard Franklin
  • Methods of sensitizing tumor cells to weak base chemotherapeutic drugs
    Patent number: 10973840
    Abstract: The invention provides a method of sensitizing a tumor cells of a subject to a weak base chemotherapeutic drug comprising administering an effective amount of a NHE6-RACK1 blocker to the subject. It also provides a method of preventing or treating cancer or a symptom thereof in a subject, comprising (a) administering an effective amount of a NHE6-RACK1 blocker to the subject; and (2) administering an effective amount of a weak base chemotherapeutic drug to the subject. Also provided are compositions and kits comprising a NHE6-RACK1 blocker.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: April 13, 2021
    Inventors: Claire Dubois, Fabrice Lucien, Pierre-Paul Pelletier